239 related articles for article (PubMed ID: 7561092)
21. Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes.
Damle NK; Klussman K; Leytze G; Aruffo A; Linsley PS; Ledbetter JA
J Immunol; 1993 Sep; 151(5):2368-79. PubMed ID: 7689606
[TBL] [Abstract][Full Text] [Related]
22. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
23. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
Tremblay N; Fontaine P; Perreault C
Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
[TBL] [Abstract][Full Text] [Related]
24. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
[TBL] [Abstract][Full Text] [Related]
25. Graft-vs-host reactions (GVHR) across minor murine histocompatibility barriers. II. Development of natural suppressor cell activity.
Maier T; Holda JH; Claman HN
J Immunol; 1985 Sep; 135(3):1644-51. PubMed ID: 3160774
[TBL] [Abstract][Full Text] [Related]
26. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
28. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
Korngold R; Leighton C; Mobraaten LE; Berger MA
Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
[TBL] [Abstract][Full Text] [Related]
29. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
[TBL] [Abstract][Full Text] [Related]
30. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice].
Wang SB; Guo KY; Hu DM; Yin B
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):810-3. PubMed ID: 16793606
[TBL] [Abstract][Full Text] [Related]
31. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
34. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
35. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
36. Reactivity of hybridomas derived from T cells activated in vivo during graft-versus-host disease.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1994 Dec; 153(11):4959-68. PubMed ID: 7963559
[TBL] [Abstract][Full Text] [Related]
37. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
[TBL] [Abstract][Full Text] [Related]
38. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
Kim W; Kim J; Jung D; Kim H; Choi HJ; Cho HR; Kwon B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):306-14. PubMed ID: 19203721
[TBL] [Abstract][Full Text] [Related]
39. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
Berger MA; Korngold R
J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
[TBL] [Abstract][Full Text] [Related]
40. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
Johnson BD; McCabe C; Hanke CA; Truitt RL
J Immunol; 1995 May; 154(10):5542-54. PubMed ID: 7730653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
